Astrazeneca Ab

Boehringer Ingelheim International Gmbh

Michael Balestra

Peter Robert Bernstein

Per Jonas Malmborg

Dirk Reinhold Weigelt

Michael Quirk

Derek Cogan

Gunnar Nordvall

Annika Kers

Jennifer Burke

Katharina Högdin

Zhidong Chen

William Frietze

Daniel Richard Marshall

Glen E Ernst

John McCauley

John Lord

Xin Guo

Bryan Patrick McKibben

David Nugiel

Kenneth Michael Meyers

Lihong Shen

Eifion D Phillips

Zhonghua Zhang

Keith R Hornberger

Yunlong Zhang

Zhaoming Xiong

Peter Allen Nemoto

Lee Fader

Maolin Yu

Jörg Martin Bentzien

David Gurley

Richard Schmiesing

James Rosamond

Hui Yu

George Byron Mullen

Kenneth M Meyers

Jörg Bentzien

Katharina HÖGDIN

Dirk Weigelt

Bryan P Mckibben

Bryan Mckibben

Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.

NMDA antagonist prodrugs

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R, R, R, R, Rand n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein X, R, Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

Aldosterone synthase inhibitors

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention is directed to ethanamine compounds, pharmaceutical compositions comprising the same, and methods of treating depression by administering the ethanamine compound.

Ethanamine compounds and methods of using the same

Ethanamine compounds and methods of using the same 545

Positive modulators of nicotinic receptor agonists

N-azabicyclo-amide derivatives

Growing community of inventors

New Fairfield, CT, United States of America

Michael Balestra